Continuing Medical Education (CME) Program

Accredited Continuing Education Program Information

The 2026 Annual Meeting, held in Denver, Colo., from May 3 - 7, is an accredited continuing education activity. Attendees who registered for CME credits and paid the processing fee are eligible to claim AMA PRA Category 1 Credit™ for attending in-person, accredited paper and cross-sectional group sessions, minisymposia, and symposia. Accredited sessions can be found in the online planner and mobile app by searching with the CME filter on.

The following Annual Meeting session types are not included in the accredited continuing education program: ARVO + Genentech Keynote series, Award lectures, Posters, and Special sessions.

All requests for credit must be submitted no later than 11:59pm U.S. Eastern Time on Friday, Aug. 28, 2026.

Exhibitors with a full-meeting badge are eligible to claim credit and should contact arvo@arvo.org for assistance.

Contact us

ARVO
General inquiries: arvo@arvo.org
CME inquiries: arvo@arvo.org
Phone: +1.240.221.2900

Physician Accreditation Statement

The Association for Research in Vision and Ophthalmology (ARVO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physician Credit Designation

ARVO designates this live activity for a maximum of 23.25 AMA PRA Category 1 Credit s ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

International Attendees

The American Medical Association (AMA) has determined that physicians not licensed in the U.S. who participate in CME activities are eligible for AMA PRA Category 1 Credit™.

Statement of Need

Ophthalmic researchers and physicians are many times unaware of and/or have limited exposure to the most recent research advances in vision and ophthalmology. This research continuously evolves toward enhancing the general understanding of the eye and visual systems, which gives rise to new pre-clinical treatment options, and revised standards of practice. Exposure to this new information is a critical first step in enhancing the understanding of basic eye functions and vision disease processes.

Target Audience

The educational design of this activity addresses the needs of basic researchers, clinician-scientists, ophthalmologists, ophthalmology residents, optometrists, post-doctoral fellows, graduate students, PhD candidates, medical students and research assistants/associates involved in the treatment of patients with eye and vision diseases and disorders.

Educational Objectives

After participating in this CME activity, participants should be able to:

• Discuss the results of basic and clinical ophthalmology investigations and vision research underway, relevant to my area of interest or practice.
• Describe new models and methods being used by researchers and practitioners in eye and vision science.
• Cite ways in which new research data and methods may influence my research and/or practice.
• Discuss prospective advancements in eye and vision research and/or practice.

European Union of Medical Specialists (UEMS) CME/CPD Requirements

European physicians can convert CME credit from the Annual Meeting to meet European Union of Medical Specialists (UEMS) CME/CPD requirements. The American Medical Association has an agreement of mutual recognition of CME credits with the UEMS, the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 Credit™ to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

Instructions to receive credit and/or certificates

Learners interested in claiming AMA PRA Category 1 Credits™ or obtain a Certificate of Participation for participating in the Annual Meeting must pay the CME Credit Fee. Payment is collected during the Meeting registration process by adding “CME Credit Fee” as a session. Attendees who do not register for CME before the conclusion of the meeting will not be able to claim and request credit. Learners registered as guests are not eligible to receive CME credit.

Credits and certificates are awarded within our ARVOLearn platform. CME registrants will receive an email with instructions prior to the start of the Annual Meeting or within two business days of your purchase (whichever is later). All requests for credit must be submitted no later than 11:59pm U.S. Eastern Time on Friday, Aug. 28, 2026.

ARVO is accredited to offer AMA PRA Category 1 Credits™ to physicians. All other participants in the CME program may receive a Certificate of Participation that documents the number of CME hours attended* by following the same instructions listed above and paying the CME credits and certificates fee.

*Some accrediting agencies may award equivalent Continuing Education (CE) credit when presented with a Certificate of Participation from an activity that offered AMA PRA Category 1 Credit™. Check with your accrediting agency for information.

Certificate of Attendance

Certificates of attendance are available free to all attendees. These certificates state that one has attended the Annual Meeting; but does not offer credit tracking. They are available for download from the Annual Meeting website.

Disclaimers

The Annual Meeting provides a forum for the open exchange and discussion of research results and scientific advancements in the field of ophthalmology; however, ARVO makes no representation or warranty as to the truth, originality, or accuracy of the information presented at the meeting or in materials distributed in connection with them. Nor are the views expressed by the individual speakers necessarily the views of ARVO. ARVO supports the ACCME’s policy on evidence-based content and encourages faculty to adhere to these standards when planning a presentation.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this meeting is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Disclaimer off-label use

The Annual Meeting may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. ARVO does not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

Financial relationship disclosures

Disclosure of relevant financial relationships

ARVO requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose all financial relationships with any ineligible company within the last 24 months. All identified relevant financial relationships are thoroughly vetted by ARVO for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

All relevant financial relationships have been mitigated by ARVO. ARVO considers presenting authors, not co-authors, to be in control of the educational content. It is ARVO’s policy and traditional scientific publishing practice to acknowledge all people contributing to the research, regardless of CME control of the live presentation of that content. ARVO may collect and publish disclosures from co-authors although they do not have control of the CME content.

Disclosures for all individuals involved in planning and managing this accredited CE activity are listed here with their relevant disclosure information. Disclosure information for presenters and session moderators will be provided within a session disclosure slide(s), prior to the start of the session and their respective presentations. The disclosure codes are defined within the Commercial Relationships Policy .

The following individuals on the Annual Meeting Program Committee (AMPC) reported no relevant financial relationships:
Arathy Kartha; Bernhard Baumann; Kostadinka Bizheva; Tasanee Braithwaite; Allen Cheong; Holly Chinnery; Jessica Cooke Bailey; Amitha Domalpally; Xin Duan; Marlies Gijs; Vishali Gupta; Samuel Herberg; Denise Inman; Joveeta Joseph-Ruben; Myeong Jin Ju; Swathi Kaliki; Kazuhiro Kurokawa; Nawajes Mandal; Milica Margeta; Ann Morris; Poonam Mudgil; Lisa Nivison-Smith; Sangita Patel; Padmanabhan Pattabiraman; Mason Posner; Aparna Raghuram; Ayellet Segre; Ruchi Sharma; Tasneem Sharma; Swati Singh; Vivek Singh; Susmit Suvas; Yih Chung Tham; William Tuten; Andrea Viczian; Frans Vinberg; Janice Walker; Yaxing Wang; Yingzi Xiong; Jason Yam; Jia Yin; Zhuoting Zhu; Elizabeth Zuniga-Sanchez

The following individuals on the Continuing Medical Education Committee (CME) reported no relevant financial relationships:
Jane W. Chan, MD; Prashant Garg, MD; Mary Whitman, MD, PhD; Jason Zhang, MD; Ditta Zobor, MD, PhD, FEBO; Wei Li; Vivek Kumar Gupta

The following activity managers reported no relevant financial relationships:
Melissa Marick, MA; Kathy Cox and Cathy Conley

The following clinical content reviewers reported no relevant financial relationships:
Katie Propst, Kim Zanon, Jennifer Guerrero, Lauren Mohar

The following activity managers and planners disclosed relevant financial relationships:
AMPC Members

Aparna Lakkaraju- Code C: Abbvie, Merck, Adverum, Sci Corp; Code P: UCSF
Bianca Maceo Heilman - Code F: Orasis Pharmaceuticals|
Bradley Dougherty- Code C: OnPoint Inc.
Brian Vanderbeek: Code C: Dompe US
Martina Herwig-Carl- Code C: Formycon
Gavin Arno-SpliceBio S.L.: (C)
Sayantan Biswas-Nidek Co Ltd (Japan): (F)
Anita Chan-ROCHE Sandcat Clinical Trial: (F); MBS Biomarkers Singapore: (F)
Jay Chhablani-Allergan: (C); Novartis: (C); Salutaris: (C); OD-OS: (C); Erasca: (C); B&L: (C); Iveric Bio: (C); Eyepoint: (C); Neurotech: (C); Ocular therapeutics: (I); AcuViz: (I); Abbvie: (I); Springer: (R); Elsevier: (R)
Natasha Frank-Rheacell: (P)
Thomas Fuchsluger-ebiga vision: (F); SIFI: (F); TRB Chemedica: (F); AbbVie: (F); Bausch & Lomb: (F); Pantherna: (F)
Eric Gaier-Luminopia: (C, P, R); Stoke Therapeutics: (C); Neurofieldz: (C)
Meredith Gregory-Ksander- ONL Therapeutics: (C); Santen Pharmaceutical Co. Ltd (F)
Mary Elizabeth Hartnett-Johnson and Johnson: (C); Ray Therapeutics: (C); Feliqs: (C); Halia; (C); Jack McGovern Coats Disease Foundation Board and chair of the scientific advisory board: (S)
Yang Hu- Pharmaron (Chengdu) Clinical Services Co., Ltd.: (C); ReNervo, Inc.: (O, Co-Founder); Qgenesys, Inc.: (C); IQVIA Inc.: (C); Character Biosciences(C)
Yi Pang: Yi Pang: Commercial Relationship(s);Essilor, Alcon, Coopervision, Sydnexis, Bausch + Lomb, Eyenovia, HOYA vision care, Sightvision, VizionFocus:Code F (Financial Support):Eyenovia
Safal Khanal-Meta Reality Labs: (F, R)
Petra Liskova-Chiesi: (C); Novartis: (C)
Alexander Ljubimov-Tarsus: (C)
Fiona McDonnell-Vialase: (C); PLU Ophthalmic: (C); Hexiris: (C); Gore Medical: (C)
Masahiro Miura-Santen: (F); Alcon: (F); Kowa: (R); Senju: (R)
Yoko Miura- Chugai Pharmaceutical Co. LTD.: (R); Ciromed: (F); Heidelberg Engineering: (F); Lightmed: (F); OD-OS GmbH; (C, F); NIDEK: (F, R); Zeiss: (F); Abbvie (R)
Minhaj Nur Alam- Code C: Alcon|
Shintaro Nakao-Alcon Japan Ltd.: (C, F, R); Bayer Yakuhin, Ltd.: (C, R); Chugai Pharmaceutical Co., Ltd.: (C, R); HANDAYA Co.Ltd.: (F); HOYA Corporation: (F); IWAKI OPTICAL.CO.,LTD.: (F); JFC Sales Plan Co.Ltd.: (F. R); Johnson & Johnson K.K.: (C); Kowa Company, Ltd.: (C, F, R); Machida Endoscope Co., Ltd.: (R); Nippon Boehringer Ingelheim Co., Ltd.: (C, R); Novartis Pharma K.K.: (C, R); Novo Nordisk Pharma Ltd.: )R); ONO PHARMACEUTICAL CO., LTD.: (R); Otsuka Pharmaceutical Co., Ltd.: (F, R); RIVERFIELD Inc.: (C); Santen Pharmaceutical Co., Ltd.: (C, F, R); Seed Inc.: (F); Senju Pharmaceutical Co. Ltd.: (C, F, R); TOMEY CORPORATION: (F); WAKAMOTO PHARMACEUTICAL CO., LTD.: (C, R)
Yoshinori Oie-Raymei: (C); Santen Pharmaceutical: (R); Otsuka Pharmaceutical: (R); Senju Pharmaceutical: (R); Japan Tissue Engineering Co., Ltd.: (R); Chugai Pharmaceutical: (R)
Mark Petrash-Research Advisory Board, Lions World Vision Institute, Tampa FL: (S)
Ethan Rossi-Robotrak Technologies, Inc.: (R)
Dorota Skowronska-Krawczyk-Visgenx: (C, P); Lucina Biotherapeutics: (O, P)
Manju Subramanian-Regeneron Pharmaceuticals: (C, F); Noble Insights: (C); I-Lumen Scientific, Inc.: (C)
Swarup Swaminathan-Abbvie: (C); Lumata Health: (C, E); Elios Vision: (C)
Kaveri Thakoor-Topcon Healthcare, Inc.: (F)
Edmund Tsui- Oculis: (C); Kodiak Sciences: (C); ANI Pharmaceuticals: (C, F); EyePoint Pharmaceuticals: (C, F); Cylite: (F, C); Kowa: (C, F); Abbvie (C); Pfizer (F)
Brian Vohnsen-Alcon: (C)
Kenji Yamashiro-Novartis Pharma: (R); Bayer Yakuhin: (R); Santen Pharmaceutical: (R); Chugai Pharmaceutical: (R); Senju Pharmaceutical: (R); Alcon Japan: (R); Kowa Pharmaceutical: (R); Boehringer Ingelheim Japan: (R); Otsuka Pharmaceutical: (R); NIDEK: (R); FINDEX: (R); Asahi Kasei Pharma: (R)

CME Committee Members

Matthew Benson, MD, MS - Novartis: (C); GSK: (C)
Sally Ong, MD - AbbVie: (C); REGENXBIO: (C); Apellis Pharmaceuticals: (C); Eyepoint Pharmaceuticals: (C); Genentech (C)
Jesse Jung - Carl Zeiss Meditec, Inc.: (C); Genentech: (R); Regeneron: (R); Astellas: (R)
Esen Akpek - Dompe: (C); Baush and Lomb: (C); Novaliq: (C); Thea: (C); Johnson and Johnson: (C); Alcon: (C); Iolyx: (C); Up-to-Date: (P); W.L. Gore: (F, R); NEI: (F); Novartis: (F); NIH: (F); Department of Defense: (F)
Hossein Ameri - Beyang Therapeutics: (C)